Kim Jaehoon, Thomas Susan Napier
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332, USA; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Cell Syst. 2024 Dec 18;15(12):1209-1224. doi: 10.1016/j.cels.2024.11.011.
Established and emergent microengineered in vitro systems enable the evaluation of chimeric antigen receptor (CAR) T cell product purity, avidity, and functionality. Here, we describe such systems and how they have been used to optimize CAR T cell products by selecting highly viable cells, eliminating off-target cells, and tailoring avidity to balance efficacy and safety. The future of CAR T cell therapy development and manufacturing is expected to be anchored in a cyclical process that integrates multiple high-throughput and patient-centered techniques for identifying, enriching, and evaluating T cell subtypes. This article explores several cutting-edge platforms and methodologies relevant to these processes.
成熟的和新兴的微工程体外系统能够评估嵌合抗原受体（CAR）T细胞产品的纯度、亲和力和功能。在此，我们描述此类系统，以及它们如何通过选择高活力细胞、消除脱靶细胞和调整亲和力以平衡疗效和安全性来优化CAR T细胞产品。CAR T细胞疗法开发和制造的未来预计将基于一个循环过程，该过程整合多种高通量和以患者为中心的技术来识别、富集和评估T细胞亚型。本文探讨了与这些过程相关的几种前沿平台和方法。
